Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab |
| |
Authors: | Au Wing-Yan Ma Edmond S Lee Tsz-Leung Ha Shau-Yin Fung Alvin T Lie Albert K W Kwong Yok-Lam |
| |
Affiliation: | Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China. |
| |
Abstract: | Thrombotic microangiopathy (TMA) is a grave complication after haematopoietic stem cell transplantation (HSCT) and effective treatment is undefined. Five patients with postHSCT TMA, which was refractory to at least 1 week of plasma exchange and prednisolone, were treated with rituximab (375 mg/m(2)/week x 4). Remission was achieved in four patients, of whom three remained in remission and one had died of sepsis at a median follow-up of 10 months. ADAMTS13 levels were low in all evaluable patients, and only one patient showed significant anti-ADAMTS13 antibody. The levels of ADAMTS13 and anti-ADAMTS13 antibody did not change significantly with rituximab-induced remission. |
| |
Keywords: | rituximab thrombotic microangiopathy haematopoietic stem cell transplantation |
本文献已被 PubMed 等数据库收录! |
|